The treatment scope for patients with metastatic castrate-resistant prostate cancer (mCRPC) is rapidly expanding. On May 15, 2013, the FDA approved radium-223 chloride for the treatment of mCRPC patients whose metastases are limited to the bones.
Introduction
Prostate cancer is the most prevalent and second deadliest cancer in men in the United States and Europe (1) . Most morbidity and virtually all mortality from prostate cancer occurs once the tumor has become metastatic and castrate-resistant (mCRPC) (2).
Therefore research aimed at the development of novel therapies for prostate cancer has primarily focused on this patient group. Whereas a decade ago no therapy existed with a proven significant benefit on the median overall survival of mCRPC patients, patients now have the options to be treated with multiple life-extending therapies. These therapies consist of agents that selectively target the androgen pathway (abiraterone acetate, enzalutamide) and taxanes (docetaxel, cabazitaxel), which target microtubules (3) (4) (5) (6) (7) (8) . Furthermore, the immunotherapy sipuleucel-T has been approved for its use in asymptomatic or minimally symptomatic mCRPC patients (9, 10) .
Prostate cancer primarily metastasizes to the bone (11) . Bone metastases may lead to severe morbidity, such as bone marrow failure, pathological fractures and spinal cord compression, reducing quality of life and potentially resulting in death (12, 13). Hence specific treatment of bone metastases may significantly lower the burden of prostate cancer disease (14, 15) . Multiple agents have been approved by the United States Food and Drug Administration (US FDA) for the palliative treatment of bone metastases in mCRPC patients, such as external beam radiotherapy and the beta-emitting radiopharmaceuticals strontium-89 (1.5-2.2 MBq/kg) and samarium-153 (37 MBq/kg) (table 1). Such therapies result in symptomatic relief in over half of patients (16, 17) .
However, the duration of response is limited; the effect of these treatments on overall
Research. On May 15, 2013, the US FDA approved radium-223 chloride (Xofigo, previously named alpharadin) for the treatment of bone metastases in mCRPC patients based on interim results from a phase III 3 randomized clinical trial, the ALSYMPCA study ("Alpharadin in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer"). This marks the first FDA approved radionuclide which has shown to extend overall survival in mCRPC patients in a phase 3 study. In this brief review, we will discuss the (pre-)clinical development of radium-223 chloride, focusing primarily on the most recent results from the ALSYMPCA study. Subsequently we will discuss the US FDA approval and future implications this approval may have in clinical practice.
Radium-223 chloride
Radium-223 chloride ( 223 RaCl 2 ) is a water soluble radium salt. In ionic form radium accumulates in bones at areas with increased bone turnover due to its chemically similar to calcium-ions; both are alkaline earth metals (18, 19) . Radium-223 is an alpha-emitting radioisotope that decays via seven daughter nuclides before it stabilizes as lead-207 ( Fig.   1 ). During the decay of each radium-223 isotope, four alpha-particles and two electrons (beta-particles) are emitted ( within 100 µm. The half-life of radium-223 is 11.4 days; the half-lives of its daughter nuclides range from seconds to minutes. These daughter nuclides do not have a chemical similarity to calcium-ions. Therefore, the half-lives of radon-219 (4.0 s), bismuth-211 (2.1 min) and thallium-207 (4.8 min) appear long enough to allow diffusion from the primary accumulation site.
Early preclinical and clinical studies
In a preclinical study, nude rats with MT-1 human breast cancer xenografts were treated with pamidronate, a bisphosphonate used against skeletal complications of cancer, with or without radium-223 (18) . While all rats treated with pamidronate only had to be sacrificed within 21 days, 40% of rats treated with pamidronate and radium-223 at 10 or 30 kBq survived beyond 50 days. Compared to beta-emitting particles such as strontium-89, rodents treated with radium-223 showed no signs of bone marrow suppression or other toxicities (20) .
In a phase 1 study, radium-223 chloride was administered to 15 prostate and 10 breast cancer patients with bone metastases (21) . Patients received a single intravenous injection of radium-223 with activities up to 250 kBq/kg. Over 50% of patients reported pain relief, while toxicity was low. Grade 3 leukopenia occurred in three patients, the maximum-tolerated dose (MTD) was not established. Radium-223 accumulated in the skeleton, particularly in sites with metastases. In the blood, radioactivity levels diminished quickly: to 6% after 1 hour and to <1% 24 hours after injection. Recently, similar findings were presented from another phase I study (22) . In this study, ten A subsequent phase 2 study compared treatment of 50 kBq/kg radium-223 with placebo treatment in 64 CRPC patients with painful bone metastases (23, 24) . Median time to skeletal-related event (SRE) was 14 weeks in the radium-223-treated group versus 11 weeks in patients treated with placebo (p = 0.257) (23) . Low toxicity of radium-223 was confirmed in this phase 2 study. None of the 33 radium-223-treated patients discontinued treatment due to adverse events. Grade 3 and 4 adverse events occurred in 3 (9.1%) and 0 (0%) radium-223-treated patients and in 1 (3.3%) and 1 (3.3%) placebotreated patients, respectively. Severe non-hematological adverse events occurred in 3 (9.1%) radium-223-treated patients and in 5 (16.7%) placebo-treated patients. In a follow-up report 24 months after the first injection of study medication, no long-term treatment-related toxicity was reported (24) . Median overall survival was 65 weeks in the radium-223-treated group, and 46 weeks in the placebo-treated group (p = 0.056).
ALSYMPCA
The ALSYMPCA phase 3 study was initiated in 2008, in which the efficacy and safety of radium-223 chloride was compared to placebo (a saline injection) in patients with symptomatic CRPC with bone metastases (25) . Patients needed to have at least two bone metastases, diagnosed by bone scintigraphy. Patients were eligible if they had previously received docetaxel, if they were unfit for docetaxel, if they declined therapy In total, 921 patients were included at 135 study locations worldwide, primarily in North America, Australia and Europe (26). Six hundred fourteen patients received radium-223, of whom 352 had received docetaxel prior to radium-223 treatment (57.3%). In the placebo-group a similar percentage had received prior docetaxel (56.6% (174 patients)).
Other baseline characteristics, such as age, disease stage and baseline opioid use, were similar between the two treatment groups as well (25) .
The primary endpoint of the ALSYMPCA study was overall survival. In general, median overall survival in patients treated with radium-223 was extended by 3.6 months compared to placebo-treated patients (p < 0.001) (25) . For patients who had received docetaxel prior to participation in the ALSYMPCA trial, median overall survival was 14. 
fractures. Time to SSE was 15.6 months in radium-223-treated patients versus 9.8 months in the placebo-treated group (p < 0.001; HR = 0.66 (95% CI 0.52-0.83)) (25) .
Time to initial opioid use and time to external beam radiotherapy were both increased in patients treated with radium-223 (HR = 0.670 and HR = 0.621, respectively) (27) .
Sixteen and 24 weeks after initiation of radium-223 treatment, patients had significantly less pain compared to baseline (p < 0.001 and p = 0.001, respectively).
Further analysis revealed that an increase in the levels of total alkaline phosphatase was associated with an increased risk for death in the patient population studied in the ALSYMPCA trial (p < 0.0001) (28) . In patients treated with radium-223, a ≥30% reduction in total alkaline phosphatase levels compared to the baseline was seen in 47% of patients versus 3% of placebo-treated patients (25) .
In general, radium-223 was well tolerated by patients, with grade 3 or 4 adverse events occurring more frequently in the placebo-treated group (62%) than in patients treated with radium-223 (56%). The only reported non-hematologic grade ≥3 adverse events that occurred more frequently in the radium-223 treated patient group, were anorexia (2% versus 1%) and a decreased appetite (2 patients versus 0 patients). Comparing grade ≥3 hematologic adverse events in the radium-223-treated group to the placebogroup, anemia occurred in 13% and 13%, neutropenia in 3% and 1%, and thrombocytopenia in 6% and 2%, respectively (25) . Analysis of these hematologic adverse events revealed that a baseline total alkaline phosphatase of ≥220 U/L strongly predicted anemia (29) . Apart from the use of radium-223 instead of placebo, other baseline predictors for neutropenia and thrombocytopenia were prior docetaxel use and more than six bone metastases. On the other hand, prior external beam radiotherapy to the bone was associated with a decrease in anemia and neutropenia.
FDA approval
Interim results from the ALSYMPCA phase 3 clinical trial resulted in approval of radium-223 by the US FDA for the treatment of mCRPC patients who have symptomatic bone metastases and no visceral metastases. It was recommended to be administered at 50 kBq/kg every 4 weeks with a maximum of 6 doses, which is equal to the treatment regimen in the ALSYMPCA trial. This approval makes radium-223 the first agent available for mCRPC patients that significantly increases overall survival by exclusively treating bone metastases.
Despite its decision to approve radium-223, the FDA required four additional studies, besides final analysis of ALSYMPCA study results (30) . Non-compliance to this decision, or negative results could result in the FDA revoking the approval.
As mentioned previously, no MTD for radium-223 has been established (21, 22) . Phase 1 studies suggested concentrations higher than 50 kBq/kg could be administered to patients with relatively few changes in the toxicity profile of the agent. Two recent phase 2 studies confirm that treatment up to 100 kBq/kg have similar toxicities compared to radium-223 at 50 kBq/kg, while the efficacy of radium-223 is increased (31, 32) . Therefore the FDA required a randomized phase 2 study to further assess the efficacy and safety of radium-223 in CRPC patients with bone metastases at concentrations higher than 50 kBq/kg. If these results suggest a beneficial risk-benefit profile for higher doses, an additional phase 3 study is required to confirm the optimal activity level.
The FDA required the company to perform three studies to further assess the safety of radium-223: an observational study in 1200 CRPC patients with bone metastases, evaluating the long-term safety of radium-223 administered at the recommended dose.
A randomized clinical trial in CRPC patients with bone metastases and no visceral metastases to further assess the safety of radium-223 was required, particularly for enhanced assessment of the effect of radium-223 on healthy bone marrow and secondary malignancies, such as acute myeloid lymphoma (AML) and myelodysplastic syndrome (MDS) (33) . Finally, to assess the short-and long-term safety of an radium-223 rechallenge, the company was required to perform a study re-treating CRPC patients with bone metastases with radium-223.
Discussion
With the US FDA approval of radium-223 chloride for CRPC patients with symptomatic bone metastases regardless of prior chemotherapy, the treatment scope for mCRPC patients has further expanded. By excluding patients with visceral metastases, the most rational step for oncologists would be to use radium-223 primarily as a first-line therapy in mCRPC patients. This said, a subpopulation may also be eligible for radium-223 treatment as second-line therapy or later.
Considering the results of radium-223 treatment in the robustly designed and well conducted ALSYMPCA trial, it is expected that the approval and consequently clinical 
use of radium-223 will expand beyond the US in the near future. Additionally, radium-223 may improve the quality of life and survival for patients with other tumor types that suffer from bone metastases. However, such expansions require additional clinical investigations. Finally, with radium-223 being the first metastasis-targeting agent approved by the US FDA based on an improved median overall survival, it confirms that selectively treating metastases may be an effective strategy in patients with advanced solid tumors for whom palliative treatment is the only option, strengthening the development of such agents.
A major limitation of the ALSYMPCA phase 3 study is that the group of patients selected for this study may not correspond to the patient population in clinical practice that will receive radium-223 treatment. Patients with visceral metastases were excluded for participation in the trial. Considering that beta-emitting radionuclides, such as samarium-153, have shown to induce pain-relief in patients with advanced prostate cancer, further research is required to address whether radium-223 provides clinical benefit for patients with visceral metastases (16, 17) . By approving radium-223, physicians may decide to administer this agent to this group of patients too, while its efficacy has not been proven. Furthermore, patients were excluded from the ALSYMPCA study when docetaxel was available, patients were fit for (and willing to receive) docetaxel-treatment and had not received docetaxel before. Nevertheless, the FDA does not exclude this group of patients for radium-223 treatment in its approval letter. Until the required post-marketing studies have been conducted which will indicate whether 
